SEC Filings

Form 10-K
VERASTEM, INC. filed this Form 10-K on 03/12/2019
Document Outline
Entire Document (8665.9 KB)
Subdocument 1 - 10-K - 10-K
Page 1 - UNITED STATES
Page 2 - TABLE OF CONTENTS
Page 3 - FORWARD LOOKING STATEMENTS
Page 4 - PART I
Page 5 - OUR FOCUS
Page 6 - Follicular Lymphoma
Page 7 - Ovarian Cancer
Page 8 - Mesothelioma
Page 9 - OUR PRODUCT AND PRODUCT CANDIDATE
Page 10 - THE COPIKTRA LABEL
Page 11 - Kaplan-Meier Curve of PFS per IRC In Patients with at Least 2 Prior Therapies (DUO)
Page 12 - Overall Response Rate (ORR) per IRC (DUO)
Page 13 - Efficacy in Patients with Relapsed or Refractory FL (DYNAMO)
Page 14 - THE DUO AND DYNAMO STUDIES
Page 15 - Median PFS per IRC for del[17p] Subpopulation
Page 16 - Median PFS by Subgroup
Page 17 - e.g.
Page 18 - *Adapted from Flinn et al., ASH 2016
Page 19 - T-cell Lymphoma, Aggressive NHL and Other Lymphomas
Page 20 - Phase 1/2 study with Cancer Research United Kingdom (CRUK) in combination with pembrolizumab.
Page 21 - Patents
Page 22 - LICENSES
Page 23 - N/A
Page 24 - Yakult Honsha Co., Ltd.
Page 25 - Pfizer Inc.
Page 26 - PI3K inhibition program
Page 27 - FAK inhibition program
Page 28 - MANUFACTURING
Page 29 - Preclinical studies
Page 30 - Marketing approval
Page 31 - Fast track designation
Page 32 - Priority review
Page 33 - in vitroin vivo
Page 34 - Combination products
Page 35 - Additional provisions
Page 36 - Pharmaceutical coverage, pricing and reimbursement
Page 37 - New legislation and regulations
Page 38 - EMPLOYEES
Page 39 - BUSINESS EXECUTIVE OFFICERS OF THE REGISTRANT
Page 40 - OUR CORPORATE INFORMATION
Page 41 - ITEM 1A. Risk Factors.
Page 42 - Preclinical testing and clinical trials of our product candidates may not be successful. In the near
Page 43 - If clinical trials of our product candidates fail to demonstrate safety and efficacy to the satisfac
Page 44 - If we experience delays or difficulties in the enrollment of patients in clinical trials, our receip
Page 45 - If serious adverse or unexpected side effects are identified during the commercialization of COPIKTR
Page 46 - Preclinical studies and preliminary and interim data from clinical trials of our product candidates
Page 47 - The approval of our product candidates as part of a combination therapy for the treatment of certain
Page 48 - If we fail to obtain regulatory approval in jurisdictions outside the United States, we will not be
Page 49 - COPIKTRA and any future product candidates that we commercialize may become subject to unfavorable p
Page 50 - If we fail to comply with our reporting and payment obligations under the Medicaid Drug Rebate Progr
Page 51 - Risks Related to Our License Agreement with Infinity
Page 52 - We will continue to need substantial additional funding. If we are unable to raise capital when need
Page 53 - Risks Related to Our Indebtedness
Page 54 - Risks Related to Our Dependence on Third Parties
Page 55 - We intend to rely on third parties to conduct investigator sponsored clinical trials of our product
Page 56 - If we are not able to establish collaborations, we may have to alter our development and commerciali
Page 57 - We may depend on collaborations with third parties for the commercialization of COPIKTRA and the dev
Page 58 - If we are unable to maintain our agreements with third parties to distribute COPIKTRA to patients, o
Page 59 - If we are unable to obtain and maintain patent protection for our products, or if our licensors are
Page 60 - We may become involved in lawsuits to protect or enforce our patents, which could be expensive, time
Page 61 - We may be subject to claims that our employees have wrongfully used or disclosed alleged trade secre
Page 62 - We have received orphan drug designation for COPIKTRA and certain of our product candidates, but the
Page 63 - We may seek fast track designation for COPIKTRA in additional indications, or for one or more of our
Page 64 - Our relationships with customers and third-party payors will be subject to applicable anti-kickback,
Page 65 - N/A
Page 66 - Our employees, independent contractors, principal investigators, CROs, consultants and vendors may e
Page 67 - Risks Related to Employee Matters and Managing Growth
Page 68 - We may expand our development, regulatory and sales and marketing capabilities over time, and as a r
Page 69 - The market price of our common stock has been, and may continue to be, highly volatile.
Page 70 - Because we do not anticipate paying any cash dividends on our capital stock in the foreseeable futur
Page 71 - Risks Related to the Notes
Page 72 - We may not have the ability to raise the funds necessary to repurchase the Notes upon a fundamental
Page 73 - Item 2. Properties
Page 74 - COMPARISON OF 5 YEAR CUMULATIVE TOTAL RETURN*
Page 75 - Item 6. Selected Financial Data
Page 76 - Item 7. Management s Discussion and Analysis of Financial Condition and Results of Operations
Page 77 - Costs of revenues, excluding amortization of acquired intangibles
Page 78 - N/A
Page 79 - Selling, general and administrative expenses
Page 80 - Revenue Recognition
Page 81 - N/A
Page 82 - Exclusive Licenses of Intellectual Property -
Page 83 - Collaborative Arrangements
Page 84 - Stock based compensation
Page 85 - Accounts Receivable, Net
Page 86 - RESULTS OF OPERATIONS
Page 87 - Selling, general and administrative expense.
Page 88 - Risk Factors,
Page 89 - N/A
Page 90 - N/A
Page 91 - Funding requirements
Page 92 - CONTRACTUAL OBLIGATIONS AND COMMITMENTS
Page 93 - RECENTLY ADOPTED ACCOUNTING STANDARDS
Page 94 - Compensation Stock Compensation (Topic 718): Improvements to Employee Share-Based Payment Accounting
Page 95 - Evaluation of Disclosure Controls and Procedures
Page 96 - Report of Independent Registered Public Accounting Firm
Page 97 - Item 9B. Other Information
Page 98 - PART III
Page 99 - PART IV
Page 100 - EXHIBIT INDEX
Page 101 - N/A
Page 102 - N/A
Page 103 - N/A
Page 104 - SIGNATURES
Page 105 - Verastem, Inc.
Page 106 - Verastem, Inc.
Page 107 - Verastem, Inc.
Page 108 - Verastem, Inc.
Page 109 - Verastem, Inc.
Page 110 - Verastem, Inc.
Page 111 - 1. Nature of business
Page 112 - Use of estimates
Page 113 - Items Measured at Fair Value on a Recurring Basis
Page 114 - Fair Value of Financial Instruments
Page 115 - N/A
Page 116 - Concentrations of credit risk and off balance sheet risk
Page 117 - Other assets
Page 118 - Revenue Recognition
Page 119 - N/A
Page 120 - Exclusive Licenses of Intellectual Property -
Page 121 - Collaborative Arrangements
Page 122 - Intangible Assets
Page 123 - Recently Issued Accounting Standards Updates
Page 124 - Recently Adopted Accounting Standards Updates
Page 125 - 3. Inventory
Page 126 - 5. Intangible assets
Page 127 - N/A
Page 128 - 8. Product revenue reserves and allowances
Page 129 - Equity offering
Page 130 - Inducement Award Program
Page 131 - Restricted Stock Units
Page 132 - 11. Convertible Senior Notes
Page 133 - N/A
Page 134 - 12. Net Loss per Share
Page 135 - N/A
Page 136 - 14. Commitments and contingencies
Page 137 - , Business Combinations,
Page 138 - Yakult Honsha Co., Ltd. (Yakult)
Page 139 - CSPC Pharmaceutical Group Limited (CSPC)
Page 140 - N/A
Page 141 - 16. Employee benefit plan
Page 142 - 17. Quarterly financial information (unaudited, in thousands, except per share data)
Page 143 - 18. Subsequent events
Subdocument 2 - EX-3.01 - EX-3.01
Page 1 - Exhibit 3.1
Page 2 - N/A
Page 3 - N/A
Page 4 - N/A
Page 5 - N/A
Page 6 - N/A
Page 7 - N/A
Subdocument 3 - EX-3.02 - EX-3.02
Page 1 - Exhibit 3.2
Page 2 - [Verastem, Inc. Amendment to Certificate of Incorporation]
Subdocument 4 - EX-21.1 - EX-21.1
Page 1 - N/A
Subdocument 5 - EX-23.1 - EX-23.1
Page 1 - N/A
Subdocument 6 - EX-31.1 - EX-31.1
Page 1 - N/A
Subdocument 7 - EX-31.2 - EX-31.2
Page 1 - N/A
Subdocument 8 - EX-32.1 - EX-32.1
Page 1 - N/A
Subdocument 9 - EX-32.2 - EX-32.2
Page 1 - N/A
Subdocument 10 - EX-99.1 - EX-99.1
Page 1 - Verastem Oncology Announces Fourth Quarter and Full-Year 2018 Financial Results and Corporate Develo
Page 2 - Key 2018 Accomplishments:
Page 3 - Signed Exclusive License Agreements in China and Japan
Page 4 - N/A
Page 5 - Fourth Quarter 2018 Financial Results
Page 6 - Important Safety Information
Page 7 - Diarrhea or Colitis:
Page 8 - Hepatotoxicity:
Page 9 - CLL/SLL:
Page 10 - About Follicular Lymphoma
Page 11 - Forward looking statements notice
Page 12 - References
Page 13 - Verastem, Inc.
Page 14 - Verastem, Inc.
XBRL Item - EX-101.INS - EX-101.INS (What's this?)
XBRL Item - EX-101.SCH - EX-101.SCH (What's this?)
XBRL Item - EX-101.CAL - EX-101.CAL (What's this?)
XBRL Item - EX-101.DEF - EX-101.DEF (What's this?)
XBRL Item - EX-101.LAB - EX-101.LAB (What's this?)
XBRL Item - EX-101.PRE - EX-101.PRE (What's this?)
XBRL Viewer